Expertise in
3
conditions

Hanneke O. Elberink

Groningen, GR, NL 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
3
conditions
Groningen, GR, NL 

Overview

Hanneke Elberink practices in Groningen, Netherlands. Elberink is highly rated in 3 conditions, according to our data. Their top areas of expertise are Mast Cell Activation Syndrome (MCAS), Systemic Mastocytosis, Anaphylaxis, and Hereditary Alpha-Tryptasemia.

Their clinical research consists of co-authoring 12 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Groningen, GR, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
Enrollment Status: Recruiting
Publish Date: January 30, 2026
Intervention Type: Drug
Study Drug: BLU-263
Study Phase: Phase 2/Phase 3
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: Completed
Publish Date: December 27, 2023
Intervention Type: Other, Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
View 1 Less Clinical Trial

12 Total Publications

Diagnosis and management of patients with mast cell activation syndromes: status 2026.
Diagnosis and management of patients with mast cell activation syndromes: status 2026.
Journal: The journal of allergy and clinical immunology. In practice
Published: August 12, 2025

Frequently Asked Questions about Hanneke O. Elberink

Is Hanneke O. Elberink a top-rated expert for Mast Cell Activation Syndrome (MCAS)?

MediFind is an objective health platform that identifies experts based on real-world data. Hanneke O. Elberink is classified as an Elite expert for Mast Cell Activation Syndrome (MCAS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Hanneke O. Elberink participate in research or clinical trials?

Yes. Hanneke O. Elberink has published 12 articles and abstracts on conditions like Mast Cell Activation Syndrome (MCAS). You can view a list of Hanneke O. Elberink's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Elberink's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile